BIONOR PHARMA ASA
STOCK EXCHANGE ANNOUNCEMENT
Notice of Extraordinary General Meeting 7 November 2016
(Oslo, Norway, 14 October 2016) An Extraordinary General Meeting of Bionor Pharma ASA will be held on Monday 7 November 2016 at 16:30 hours at KS Agenda Møtesenter, Haakon VIIs gate 9 in Oslo, Norway.
Due to the recent issuance of new shares in the private placement and the rights offering the current authorization to the Board to issue new shares is in the view of the board insufficient. The Board finds it necessary that the company has flexibility to issue new shares on short notice in order to be able to obtain additional funding for the Company, strategic measures and/or future operations. The Board accordingly call the EGM to propose to the shareholders to resolve a new authorization to the Board to issue shares in the Company.
The notice of the Extraordinary General Meeting on 7 November 2016 is attached hereto and includes detailed registration and proxy instructions.
All relevant documents and link to online registration of attendance and advance voting can be found on www.bionorpharma.com .
Please note that to attend the Extraordinary General Meeting, attendants must be registered shareholders five working days prior to the meeting - 31 October 2016.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Unni Hjelmaas, Acting CEO, +47 915 19 651, email@example.com
Bionor Pharma's mission is to enable the immune system to fight HIV infection. Bionor is the first company, which has successfully completed a clinical trial using the shock and kill approach, thereby creating a strong foundation for further advancing its therapeutic vaccine Vacc-4x in combination with other agents towards a functional cure. The company believes it has first mover potential based on clinical results to date and early adoption of the shock and kill strategy. In December 2015, Bionor announced that the HIV trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor currently retains full ownership rights to the HIV immunotherapy Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company's shareholders. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com .
Last updated on: 15/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.